Chapter 1: Effectiveness of each element of the comprehensive geriatric assessment (CGA): English translation of the Japanese CGA-based healthcare guidelines 2024

Abstract

Is screening with the comprehensive geriatric assessment (CGA) useful in older adults?

The following were considered important in developing recommendations for this CQ: reduction in mortality for outpatients, inpatients, and institutionalized patients, reduction in the length of stay, improvement in polypharmacy, and increase in costs.

Is ADL assessment useful in older adults?

The following were considered important in developing recommendations for this CQ: reducing mortality for outpatients, inpatients, and institutionalized older adults, increasing institutionalization, increasing costs, and optimizing care services.

Is it useful to assess the CGA in older adults using cognitive assessment tools?

The following were considered important in developing recommendations for this CQ: improving the diagnosis rate of dementia, improving the diagnosis rate of mild cognitive impairment, optimizing comorbidity management, and increasing costs.

Is depression assessment useful in older adults with physical disease? Which depression scales are useful?

The following were considered important in developing recommendations for this CQ: reduction in mortality and hospital admission/readmission rates that could be identified as outcomes. A study on improving polypharmacy was used as a reference for the recommendations.

Is it useful to assess motivation in older adults with possible apathy? Which measures of motivation are useful?

The following were considered important in developing recommendations for this CQ: physical and motor function that could be identified as an outcome.

Is it advisable to assess the QOL in older adult care?

Are interventions based on the assessment of social factors useful in older adults?

The following were considered important in developing recommendations for this CQ: improving QOL, increasing costs, and improving ADLs as a result of interventions based on social factors.

The following were considered important in developing recommendations for this CQ: optimizing care services, improving ADLs, optimizing management of comorbidities, and increasing costs.

The following were considered important in developing recommendations for this CQ: optimizing care services, improving ADLs, improving nutritional status, increasing costs, and increased costs were considered important.

SO received lecture fee from Daiichi Sankyo. SI received funding from Nihon Kijyun Shingu, Sompo Care, and Hoshizaki. KM received lecture fees from Eisai and Tsumura. HU received research funding from Astellas Pharma, Abbott Japan, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Merck & Co., Fukuda Lifetech, FUJIFILM Toyama Chemical, FUJIFILM RI Pharma, Kracie, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Sumitomo Dainippon Pharma, Takeda, and Tsumura. MA received research funding from Astellas Pharma, Bayer Yakuhin, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Merck & Co., Fukuda Lifetech, Kracie, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, Takeda, and Tsumura, manuscript fees from Daiichi Sankyo, and lecture fees from Daiichi Sankyo, Merck & Co., Toa Eiyo, and Towa Pharmaceutical. The other authors declare no conflict of interest.